Modular cleanroom company GermFree and non-profit Caring Cross have announced a new partnership, hoping to make cellular gene therapies more available to patients.

The companies plan to create a decentralised, point-of-care manufacturing model that combines GermFree’s mobile cleanroom units with Caring Cross’s manufacturing technologies and pipeline of cellular gene therapy products.

The partnership builds on three years of preparation, including a pilot project with Brazil’s Fundação Oswaldo Cruz (Fiocruz) to launch local CAR-T manufacturing next year.

The current cost of CAR-T cell therapies starts at $350,000, with some patient-specific therapies exceeding $3 million. GermFree and Caring Cross aim to significantly reduce these costs by developing a point-of-care manufacturing model and partnering directly with local governments and institutions.

The production process for CAR-T therapies is highly complex, requiring multiple transfers and stringent regulatory compliance at each stage. By enabling the entire manufacturing process nearer to any patient’s location, the partners hope the mobile cleanrooms will allow local teams to make the therapies, with the potential to skip steps like cryopreservation and long-distance cold-chain shipping.

The collaboration will also focus on minimising the time from initial blood collection to the final infusion, enhancing treatment outcomes.

Improving access to CAR-T

Boro Dropulić, Executive Director and Co-Founder of Caring Cross, commented: “With a modest investment, clinical centres and affiliated organisations can leverage their existing capabilities to produce CAR-T and other CGT products sustainably and affordably. Our goal is to empower these centres to provide life-saving therapies at a fraction of the current cost.”

The partners aim to make cellular gene therapies available in remote and underserved locations, bridging gaps in current industry capabilities.

Carol Houts, Chief Strategy Officer at GermFree, said: “We often hear that innovation leads to affordability, but patients have been suffering while they wait. The technology for mobile cleanrooms with stringent quality management systems is ready. This partnership aims to inspire the industry to advance and demonstrate that CAR-T and other cell therapies can be made accessible globally, regardless of regional wealth disparities.”

Diana Spencer, Senior Digital Content Editor, DDW